Principal Financial Group’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Principal Financial Group’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-29,760	Closed	-$600K	–	2691
2021 Q3	$600K	Buy	29,760 +1,132	+4%	+$31.3K	﹤0.01%	2126
2021 Q2	$1.07M	Sell	28,628 -1,983	-6%	-$60.8K	﹤0.01%	2024
2021 Q1	$783K	Sell	30,611 -1,533	-5%	-$39.2K	﹤0.01%	2046
2020 Q4	$708K	Buy	32,144 +17,833	+125%	+$393K	﹤0.01%	2023
2020 Q3	$257K	Sell	14,311 -11,416	-44%	-$236K	﹤0.01%	2154
2020 Q2	$653K	Buy	25,727 +15,297	+147%	+$330K	﹤0.01%	1908
2020 Q1	$192K	Buy	10,430 +451	+5%	+$8.77K	﹤0.01%	2067
2019 Q4	$220K	Buy	+9,979	New	+$201K	﹤0.01%	2118

Other funds holding DRNA

CAM

Close Asset Management London, United Kingdom $3.69B AUM 21.62% 1-Year Est. Return

Principal Financial Group's DRNA Position: Q4 2021 in Review

Principal Financial Group sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 29,760 shares — an estimated $600K sold.

Principal Financial Group first reported a position in DRNA in Q4 2019 and held it in 8 quarters. The position peaked at $1.07M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

Principal Financial Group reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
Principal Financial Group sold 29,760 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $600K.
Principal Financial Group first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 8 quarters.
Principal Financial Group's Dicerna Pharmaceuticals, Inc. position peaked at $1.07M in Q2 2021.
1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Principal Financial Group's 13F filing for Q4 2021, filed 9 Feb 2022.